Globe Life (GL)
NYSEFinancialsInsurance - LifeSnapshot 2026-07-07
$176.73-0.14%
Close 2026-07-07 · 1-day change
Reading GL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GL free→NYSEFinancialsInsurance - LifeSnapshot 2026-07-07
Reading GL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GL free→QuarterlyIQ Insights · GL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $176.73. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $177 GL trades at 2.3× p/b, in line with its 2.1× p/b peer median, and our $194 fair value agrees. It's a high-confidence read. Analysts target $175–$185. Note: our $194 fair value sits above the entire analyst range ($175–$185). Not investment advice.
$175.00 – $185.00 (median $181.00) · 3 analysts · as of 2026-05-26
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $181.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $198.15 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $192.49 | — | — | Hist. CAGR | high |
| graham number | 12M | $159.94 | — | — | TTM | high |
| Mgmt guidance | 12M | $258.98 | 16.5 | 15.65 | Mgmt | high |
| Peer P/B | 12M | $160.09 | 2.1 | 76.30 | TTM | high |
| Peer P/FCF | 12M | $209.81 | 13.6 | 15.42 | TTM | high |
| Peer P/E | 12M | $246.57 | 16.5 | 14.90 | TTM | high |
| Peer P/S | 12M | $257.01 | 3.4 | 76.17 | TTM | high |
| PEG | 12M | $222.42 | 14.9 | 14.90 | TTM | high |
| residual income | 12M | $111.22 | — | — | TTM | high |
| Own P/E history | 12M | $170.76 | 11.5 | 14.90 | TTM | high |
| triangulated | 12M | $250.96 | 16.5 | 15.17 | Triangulated | high |
| Mgmt guidance | 3Y | $324.24 | 16.5 | 19.59 | Mgmt(prov.) | medium |
| Peer P/B | 3Y | $243.48 | 2.1 | 116.05 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 3Y | $175.14 | 13.6 | 12.87 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $310.54 | 16.5 | 18.77 | Analyst | medium |
| Peer P/S | 3Y | $324.01 | 3.4 | 96.02 | Analyst | medium |
| PEG | 3Y | $280.13 | 14.9 | 18.77 | Analyst | medium |
| Own P/E history | 3Y | $215.06 | 11.5 | 18.77 | Analyst | medium |
| Mgmt guidance | 5Y | $376.64 | 16.5 | 22.76 | Mgmt(prov.) | high |
| Peer P/B | 5Y | $322.00 | 2.1 | 153.48 | Hist. CAGR(prov.) | high |
| Peer P/FCF | 5Y | $155.27 | 13.6 | 11.41 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $361.21 | 16.5 | 21.83 | Analyst | high |
| Peer P/S | 5Y | $376.87 | 3.4 | 111.69 | Analyst | high |
| PEG | 5Y | $325.83 | 14.9 | 21.83 | Analyst | high |
| Own P/E history | 5Y | $250.15 | 11.5 | 21.83 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.